12 Jan MEDIMMUNE ENTERS LICENSING AGREEMENT WITH OMNIS PHARMACEUTICALS FOR ONCOLYTIC VIRUSES IN IMMUNO-ONCOLOGY
January 12th, 2015 — AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV). The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.
Oncolytic viruses are designed to target tumour cells with the killing potency of viruses. VSV is among a group of naturally occurring viruses that can be engineered to selectively infect tumour cells and destroy them without harming healthy cells. These oncolytic viruses represent a potentially powerful new tool in the fight against cancer and may be synergistic with various immunotherapies currently being developed by MedImmune.
Under the terms of the agreement, MedImmune has the license to develop and, if successful, to commercialise Omnis’s lead oncolytic virus programme. Clinical development of the virus will be accelerated with the objective of rapidly progressing to combination studies with MedImmune’s immunotherapy molecules.
Dr. Edward Bradley, Senior Vice President, R&D, and Head of MedImmune’s Oncology Innovative Medicines Unit, said: “Oncolytic viruses combine potent tumour cell killing with increasing the visibility of the tumour cell to the immune system. Our immunotherapy molecules offer the prospect of boosting the cancer-killing abilities of these viruses by enhancing the anti-cancer effect.”
“We believe that MedImmune’s portfolio of immunotherapeutic agents, which harness the ability of the immune system to attack cancer cells, will produce beneficial synergies with our VSV programme,” said Stephen J. Russell, Chief Executive Officer, Omnis Pharmaceuticals. “We are taking advantage of the immense ‘intelligence’ of viruses and the immune system, which are usually in conflict with each other, to combat another resourceful adversary, the tumour.”
NOTES TO EDITORS
About Omnis Pharmaceuticals
Omnis Pharmaceuticals is a clinical stage biotechnology company dedicated to delivering groundbreaking virus-based therapies for cancer patients in need. Omnis’ lead program employs the VSV (vesicular stomatitis virus) platform, which has been strategically engineered to selectively destroy cancer without harming normal tissues. Omnis is based in Rochester, Minnesota. For more information, please visit www.omnispharma.com.
MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please visit www.medimmune.com.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Esra Erkal-Paler: +44 20 7604 8030 (UK/Global)
Ayesha Bharma: +44 20 7604 8034 (UK/Global)
Karen Birmingham: +44 20 7604 8120 (UK/Global)
Jacob Lund: +46 8 553 260 20 (Sweden)
Tracy Rossin: + 1 301 398 1468 (MedImmune)
Thomas Kudsk Larsen: +44 20 7604 8199 mob: +44 7818 524185
Karl Hård: +44 20 7604 8123 mob: +44 7789 654364
Eugenia Litz: +44 20 7604 8233 mob: +44 7884 735627
Craig Marks: +44 20 7604 8591 mob: +44 7881 615764
Christer Gruvris: +44 20 7604 8126 mob: +44 7827 836825
James M Hannon: +1 612 812 2681